がん関連疲労を伴う小児脳腫瘍の生存者におけるメチルフェニデート (EMBRAIN)
小児期または青年期に脳腫瘍の治療を受けた患者の癌関連疲労に対するメチルフェニデートの効果:無作為化、二重盲検、プラセボ対照クロスオーバー試験のプロトコル - embrain試験
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.
The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).
If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Sebastian W Most-Mottelson, MD, PhD Student
- 電話番号:+45 21567257
- メール:sebastian.wenzel.most-mottelson@rsyd.dk
研究連絡先のバックアップ
- 名前:Mathias Rathe, Consultant, MD, PhD
- 電話番号:+45 20469682
- メール:mathias.rathe@rsyd.dk
研究場所
-
-
-
Aalborg、デンマーク、9000
- 募集
- Aalborg University Hospital
-
コンタクト:
- Christina Friis Jensen, Consultant, MD
- 電話番号:+45 97663368
- メール:cfj@rn.dk
-
主任研究者:
- Christina Friis Jensen, Consultant, MD
-
Aarhus、デンマーク、8200
- 募集
- Aarhus University Hospital
-
コンタクト:
- Louise T Henriksen, MD, PhD
- 電話番号:+45 20921611
- メール:louhen@rm.dk
-
主任研究者:
- Louise T Henriksen, MD, PhD
-
Copenhagen、デンマーク、2100
- 募集
- Rigshospitalet
-
コンタクト:
- Christine Dahl, Consultant, MD, PhD
- 電話番号:+45 35454137
- メール:christine.dahl@regionh.dk
-
主任研究者:
- Christine Dahl, Consultant, MD, PhD
-
Odense、デンマーク、5000
- 募集
- Odense University Hospital
-
コンタクト:
- Mathias Rathe, Consultant, MD, PhD
- 電話番号:+45 20469682
- メール:mathias.rathe@rsyd.dk
-
主任研究者:
- Sebastian W Most-Mottelson, MD, PhD Student
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
- Treated for a brain tumor during the previous 10 years.
- Age ≥6 years and <28 years at the start of the trial.
- Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
- No known signs of clinical or radiological tumor progression at last follow-up.
- Danish is the sole or primary language (enabling provision of validated assessment tools).
- Patient and family have provided consent for inclusion in the trial.
- Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
- History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.
Exclusion Criteria:
-
Any known contraindications to methylphenidate as outlined below:
A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.
-
History of recent poorly controlled seizures.
-
Complex tics or Tourette syndrome (including family history of tic disorder).
-
Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.
-
Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.
-
Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.
-
Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.
-
Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).
-
Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Methylphenidate, Then Placebo
Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments. |
10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol. 10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate). |
|
実験的:Placebo, Then Methylphenidate
Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments. |
10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol. 10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate). |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PedsQL Multidimensional Fatigue Scale (MFS)
時間枠:At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS). |
At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PedsQL Multidimensional Fatigue Scale (MFS)
時間枠:At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS. |
At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
|
Behaviour Rating Inventory of Executive Function (BRIEF)
時間枠:At baseline, at Week 6, and Week 16.
|
Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire. |
At baseline, at Week 6, and Week 16.
|
|
Connor's Continuous Performance Test (CPT) Online Suite
時間枠:At baseline, at Week 6, and Week 16.
|
Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used. |
At baseline, at Week 6, and Week 16.
|
|
Wechsler Coding
時間枠:At baseline, at Week 6, and Week 16.
|
Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant. |
At baseline, at Week 6, and Week 16.
|
|
Wechsler Digit Span
時間枠:At baseline, at Week 6, and Week 16.
|
Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant. |
At baseline, at Week 6, and Week 16.
|
|
PedsQL Generic Core Scales
時間枠:At baseline, at Week 6, and Week 16.
|
Changes from baseline in self and parent-reported measures of Health Related Quality of Life. |
At baseline, at Week 6, and Week 16.
|
|
Accelerometry (Axivity AX3)
時間枠:Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
|
Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used. |
Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
|
|
Barkley's Stimulant Side Effect Rating Scale (SSERS)
時間枠:At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..
|
Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used. |
At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..
|
協力者と研究者
協力者
捜査官
- スタディディレクター:Mathias Rathe, Consultant, MD, PhD、Odense University Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 24/51848
- R352-A20781 (その他の助成金/資金番号:The Danish Cancer Society)
- 2023-001094 (その他の助成金/資金番号:The Danish Childhood Cancer Foundation)
- 2023-507926-18-00 (Ctis)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。